Fact CheckerSign in

NCT07447960Completed

LRFN5 and OLFM4 in Schizoaffective Disorder

LRFN5 and OLFM4 Levels in Schizoaffective Disorder: A Cross-Sectional Case-Control Study

Source: ClinicalTrials.gov · Last updated 10 Sept 2026

Brief summary (registry, in English)

Schizoaffective disorder (SAD) is a chronic psychiatric condition characterized by psychotic and mood symptoms. Emerging evidence suggests that Leucine-Rich Repeat and Fibronectin Type-III Domain-Containing Protein 5 (LRFN5) and olfactomedin-4 (OLFM4) may play roles in synaptic organization, neurodevelopment, and neuroinflammation. However, no prior study has investigated these biomarkers in SAD. This cross-sectional case-control study aims to compare peripheral serum levels of LRFN5 and OLFM4 in subjects diagnosed with SAD in remission and healthy control subjects. The study also assessed associations between these biomarkers and clinical symptom severity, global functioning, and systemic inflammation measured by the Aggregate Index of Systemic Inflammation (AISI). The study aimed to investigate convergent synaptic and immunoinflammatory dysregulation in SAD.

Status (registry)
Completed
Study type
Observational
Enrollment
110 (actual)
First submitted
26 Feb 2026
Start date
2 Mar 2026
Primary completion date
2 Jun 2026
Lead sponsor
Elazığ Mental Health and Diseases Hospital
NCT number
NCT07447960

What you commit to

  • Study type: Observational
  • Participants enrolled: 110
  • From 2 Mar 2026 to the primary completion date, 2 Jun 2026
  • 1 site in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Criteria the registry did not label

  • For Schizoaffective Disorder (SAD) Group:
    • \*Inclusion Criteria:
    • Diagnosis of SAD according to DSM-5-TR
    • Acute manic episode
    • Medication-free for at least one month prior to admission
    • Age ≥ 18 years and \<65 years
    • Provided informed consent
    • For Schizoaffective Disorder (SAD) Group:
    • \*Exclusion Criteria:
    • Hypertension
    • Diabetes mellitus
    • Chronic kidney disease
    • Rheumatoid arthritis
    • Systemic lupus erythematosus
    • Cardiac illness
    • Severe neurological disorders
    • Immunological or systemic illness
    • Primary psychiatric disorders other than SAD
    • Alcohol/drug/substance use
  • For Healthy Control Group:
    • \*Inclusion Criteria:
    • No psychiatric diagnosis
    • No systemic or immunological illness
    • Medication-free for at least one month
    • Age ≥ 18 years and \< 65 years
    • Provided informed consent
    • For Healthy Control Group:
    • \*Exclusion Criteria:
  • Hypertension
  • Diabetes mellitus
  • Chronic kidney disease
  • Rheumatoid arthritis
  • Systemic lupus erythematosus
  • Cardiac illness
  • Severe neurological disorders
  • Immunological or systemic illness
  • Having psychiatric disorders
  • Alcohol/drug/substance use

Age in the registry: 18 years to 65 years · Sex: All · Accepts healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
Elazığ Mental Health and Diseases Hospital Psychiatry Clinic
Coordinator of this site? Confirm its status		ElâzığTurkey (Türkiye)Unknown status

This page is information, not medical advice. Discuss any trial with your doctor.